

Validation data for Jurkat-Lucia™ NFAT-CD16-Low Cells

<https://www.invivogen.com/jurkat-lucia-nfat-cd16-cells>

For research use only

Version 23J25-AK

Jurkat-Lucia™ NFAT-CD16-Low cells were engineered from the human T-lymphocyte Jurkat cell line and designed as reporter cells for antibody-dependent cellular cytotoxicity (ADCC). Nuclear translocation of NFAT (nuclear factor of activated T-cells), a transcription factor naturally expressed by Jurkat cells, is an early signaling event in ADCC induction. Jurkat-Lucia™ NFAT-CD16-Low cells stably express the cell surface Fc receptor CD16A (FcγRIIIA; F158 low-affinity allotype) and the Lucia luciferase reporter gene under the control of an ISG54 minimal promoter fused to six NFAT response elements. Human CD16A expression by Jurkat-Lucia™ NFAT-CD16 cells has been verified by flow-cytometry. These cells have been functionally tested with the Raji-Null target cell line (expressing CD20) and Anti-hCD20 IgG isotypes. Antibodies displaying lower EC₅₀ have higher ADCC potency (Figure 1).

Jurkat-Lucia™ NFAT-CD16-Low cell responses to ADCC induction with anti-human CD20 isotypes and Raji-hCD20 target cells




Figure 1. Comparison of ADCC potency for native and engineered anti-human CD20 isotypes. Raji-Null cells were incubated with gradient concentrations of Anti-hCD20 or Anti-β-galactosidase (β-gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16-Low effector cells were then co-incubated with target cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3622-3480
E-mail: info@invivogen.com